Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114924 | 0.83 | ATM (0.57) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL6115037 | 0.80 | ATM (0.63) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL3636909 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL3347670 | 0.79 | L3MBTL1 (0.61) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL11322378 | 0.79 | PDE10A (0.46) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL2908675 | 0.78 | L3MBTL1 (0.51) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL3639574 | 0.78 | PDPK1 (0.54) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL13977557 | 0.78 | ATM (0.51) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL3823640 | 0.78 | ATM (0.51) | CYP1A2CYP2A6ATML3MBTL1PDE10A | |
| SCHEMBL1999306 | 0.78 | ATM (0.51) | CYP1A2CYP2A6ATML3MBTL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796800-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-10-24 | — | — | US | claimed |
| US-20160108153-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| US-9249244-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2016-02-02 | — | — | US | claimed |
| EP-2619233-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2013-07-31 | — | — | EP | claimed |
| WO-2012040026-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | WO | claimed |
| WO-2024106914-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | WO | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230322815-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITY OF HUDDERSFIELD (GB) | 2023-10-12 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070299059-A1 | Compostions and methods relating to novel compounds and targets thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-12-27 | — | — | US | disclosed |
| US-7276348-B2 | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299059-A1 | Compostions and methods relating to novel compounds and targets thereof | CASP1, BAX, BAD | CYP1A2 676/4885CYP2A6 1205/4885ATM 4393/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CYP1A2 3406/4885CYP2A6 2545/4885ATM 3869/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | CYP1A2 572/4885CYP2A6 785/4885ATM 3400/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | CYP1A2 48/4885CYP2A6 49/4885ATM 4735/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | CYP1A2 4591/4885CYP2A6 3981/4885ATM 1516/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CYP1A2 1500/4885CYP2A6 1431/4885ATM 1529/4885 |
| US-20230322815-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | BRCA1, TPX2, XPA | CYP1A2 731/4885CYP2A6 1447/4885ATM 2155/4885 |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | CYP1A2 4416/4885CYP2A6 4058/4885ATM 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.